UPDATE: Jazz Pharma Says 'treatment-emergent adverse events that occurred in ≥5% of patients who received JZP-258 were headache, nausea, dizziness, cataplexy, nasopharyngitis, decreased appetite, influenza, diarrhea and vomiting'
Benzinga Newsdesk